期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

硼替佐米及沙利度胺联合治疗对新发骨髓瘤患者肾功能的影响 被引量：1

暂未订购
导出
摘要 目的观察大剂量地塞米松为基础的常规化疗和加用硼替佐米及沙利度胺治疗后对新发骨髓瘤患者伴肾功能衰竭的影响。方法将41例新发伴肾功能衰竭的骨髓瘤患者分为两组，均应用大剂量地塞米松为基础的化疗方案。常规化疗组（n=27）患者接受VAD（长春新碱、阿霉素、地塞米松）或VAD类似方案；新药组（n=14）在大剂量地塞米松治疗基础上加用硼替佐米和（或）沙利度胺治疗，比较两组患者在用药前后。肾功能损害的改善情况。结果常规化疗组对初治骨髓瘤肾功能不全的肾功能好转率为48．1％，中位缓解时间为1．8个月，新药组的肾功能好转率85．7％，中位缓解时间为1．4个月，使肾功能更快获得缓解。结论大剂量地塞米松为基础的化疗方案对新发骨髓瘤患者的肾功能衰竭逆转率高，加用沙利度胺和硼替佐米治疗骨髓瘤患者可使肾功能更快好转，对骨髓瘤的治疗反应好于常规化疗组。
作者 高大 肖镇
机构地区 内蒙古医科大学附属医院血液科
出处 《临床内科杂志》 CAS 2013年第2期126-128,共3页 Journal of Clinical Internal Medicine
关键词 骨髓瘤 肾衰竭 地塞米松 沙利度胺 硼替佐米
分类号 R692.5 [医药卫生—泌尿科学]
  • 相关文献

参考文献6

  • 1Raab MS, Podar K, Breitkreutz I, et al. Multiple myeloma. Lancet, 2009,374:324-339.
  • 2Kyle RA, Gertz MA, Witzig TE,et al. Review of 1027 patients with newly diagnosed multiple mveloma. Mayo Clin Proc,2003,78:21-33.
  • 3熊文杰,冯春锐,凌燕,刘焕勋,游伟文,卓家才.硼替佐米联合地塞米松治疗多发性骨髓瘤26例临床分析[J].中国医师杂志,2012,14(6):835-837. 被引量：7
  • 4Moumas E,Hanf W, Desport E, et al. New insights in the treatment of myeloma with renal failure. Nephrol Ther,2011,7 :457-466.
  • 5Roussou M, Kastritis E, Christoulas D, et al. Reversibility of renal fail- ure in newly diagnosed patients with multiple myeloma and the role of novel agents. Leuk Res ,2010,34 : 1395-1397.
  • 6陈海飞,李征洋,秦龙梅,崔庆亚,任永亚,沈红石,唐杰庆,王静,丁洁,吴天勤.改良VTD方案治疗老年多发性骨髓瘤的效果及安全性分析[J].中国综合临床,2012,28(12):1252-1254. 被引量：7

二级参考文献17

  • 1Blade J,Samson D, Reeee D, el al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietie stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant [ J]. Br J Haematol, 1998, 102(5) :1115-1123.
  • 2Liu YJ, Zhu GP, Guan XY. Comparison of the NCI-CTCAE version 4.0 and version 3.0 in assessing chemoradiation-induced oral mucositis for locally advanced nasopharyngeal carcinoma [ J ]. Oral 0ncol,2012,48(6) :554-559.
  • 3Richardson PG, Sonneveld P, Schuster M, et al. Extended follow-up of a phase 3 trial in relapsed multiple myeloma:final time-to-event results of the APEX trial [ J ]. Blood,2007,110 (10) :3557-3560.
  • 4Pineda-Roman M, Zangari M, van Rhee F, et al. VTD combination therapy with is highly effective in advanced and refractory multiple myeloma [J]. Leukemia,2008,22(7) : 1419-1427.
  • 5San Miguel JF, Schlag R, Khuageva NK, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma [J]. N Engl J Med,2008,359(9) :906-917.
  • 6Richardson PG, Xie W, Mitsiades C, et al. Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy [J]. J Clin Oncol,2009,27(21 ) :3518-3525.
  • 7Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma [ J ]. N Engl J Med, 1999,341 (21) :1565-1571.
  • 8Glasmacher A, Hahn C, Hoffmann F, et al. A systematic review of phase-II trims of thalidomide monotherapy in patients with relapsed or refractory multiple myeloma [ J ]. Br J Haematol,2006,132 (5) : 584-593.
  • 9Alexanian R, Barlogie B, Dixon D. High-dose glucocorticoid treatment of resistant myeloma [J]. Ann Intern Med, 1986, 105 (1) :8-11.
  • 10Mateos MV, Oriol A, Martinez - Lopez J, et al. Bortezomib, melphalan, and prednisone versus bortezomih, thalidomide, and prednisone as induction therapy followed by maintenance treatment with hortezomih and thalidomide versus hortezomih and prednisone in elderly patients with untreated multiple myeloma: a randomisod trial [ J ]. Lancet Onco1,2010,11 ( 10 ) :934-941.

共引文献12

同被引文献3

引证文献1

临床内科杂志
2013年 第2期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部